Sector News

Novartis taps Amazon know-how for ‘smart’ manufacturing, supply chain

December 5, 2019
Life sciences

Novartis has joined forces with Amazon, drawing on the online retail giant’s technological wizardry to reduce bottlenecks and improve the efficiency of its manufacturing and distribution.

The deal with Amazon Web Services (AWS) is aimed at using the tech company’s cloud-based systems to collect inventory, quality, and production data across its network into central hubs, dubbed Insight Centres, that Novartis says will help it to track production in real time.

The increase in efficacy is essential in light of a shift in the industry towards the production of personalised therapies – such as Novartis’ CAR-T Kymriah (tisagenlecleucel) for blood cancers – which are more complex to make than conventional drugs.

For Novartis, partnering with AWS buys into the many years Amazon has spent developing supply chain and automation systems that enable millions of products to be delivered to hundreds of millions of individuals.

Financial terms of the deal – which comes four years after the two companies first started working together – aren’t being disclosed. The deal also follows Novartis’ wide-ranging partnership with Microsoft to develop artificial intelligence tools for use in its R&D operations.

Novartis’ global head of strategy and operations Amit Nastik said pharma manufacturing as a whole is not as advanced as manufacturing in other industries, and because it is highly regulated “there is a natural hesitancy to try technology that is not fully proven.”

“The Insight Centres will allow us to look at our whole value chain from the start to the end, from how we source our material, how we do our demand forecasting, how we operate at the shop floor, to how we supply our customers and patients,” he added.

For instance, Novartis plans to use AWS Internet of Things (IoT) services to develop better visual inspections of manufacturing sites by generating images that can be analysed using computer vision algorithms.

That will improve its ability to monitor for risks to manufacturing production, such as unplanned downtime or delayed orders.

Meanwhile, for Amazon the deal marks another element of its push into the healthcare sector with deals such as its recent purchase of online symptom checking and triage tool specialist Health Navigator, and online pharmacy player PillPack.

By Phil Taylor

Source: PharmaPhorum

comments closed

Related News

September 25, 2022

Rise of the machines: Novo Nordisk pledges $200M to create first quantum computer for life sciences

Life sciences

Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.

September 25, 2022

Mount Sinai AI uncovers new brain analysis method to predict dementia, Alzheimer’s disease

Life sciences

Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.

September 25, 2022

New AstraZeneca-backed report finds big money behind diverse owners and entrepreneurs in Europe

Life sciences

There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.